US20150329622A1 - Anti-bag3 antibodies for therapeutic use - Google Patents

Anti-bag3 antibodies for therapeutic use Download PDF

Info

Publication number
US20150329622A1
US20150329622A1 US14/651,213 US201414651213A US2015329622A1 US 20150329622 A1 US20150329622 A1 US 20150329622A1 US 201414651213 A US201414651213 A US 201414651213A US 2015329622 A1 US2015329622 A1 US 2015329622A1
Authority
US
United States
Prior art keywords
bag3
antibody
pharmaceutical composition
diseases
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/651,213
Other languages
English (en)
Inventor
Maria Caterina Turco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biouniversa SRL
Original Assignee
Biouniversa SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biouniversa SRL filed Critical Biouniversa SRL
Assigned to BIOUNIVERSA S.R.L. reassignment BIOUNIVERSA S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TURCO, MARIA CATERINA
Publication of US20150329622A1 publication Critical patent/US20150329622A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the present invention relates to the use of Anti-BAG3 antibodies as a medicament, in particular for use in the treatment of pancreatic tumours or other pathologies of an immune, inflammatory, neoplastic and/or degenerative nature.
  • BAG3 protein is a 74 kDa cytoplasmic protein which belongs to the family of co-chaperonins that interact with the ATPase domain of the protein HSP70 (Heat Shock Protein) through the structural domain known as the BAG domain (amino acids 110-124). Furthermore, BAG3 protein contains a WW domain (Trp-Trp), a proline-rich region (PXXP), and two conserved motifs IPV (Ile-Pro-Val), which can mediate binding to other proteins. Thanks to the nature of BAG3 protein as an adapter, attributable to the presence of many functional domains, such protein can therefore interact with different proteins.
  • bag3 gene expression is constitutive for a few kinds of normal cells, including myocytes, while mutations thereof are associated with diseases of the skeletal and cardiac muscles. Furthermore, BAG3 protein is expressed in many types of primary tumours or tumour cell lines (lymphoid or myeloid leukemias, neuroblastoma, pancreatic cancer, thyroid cancer, breast cancer and prostate cancer, melanoma, osteosarcoma, glioblastoma and tumours of the kidney, colon, and ovary).
  • primary tumours or tumour cell lines lymphoid or myeloid leukemias, neuroblastoma, pancreatic cancer, thyroid cancer, breast cancer and prostate cancer, melanoma, osteosarcoma, glioblastoma and tumours of the kidney, colon, and ovary.
  • bag3 gene expression can be induced by stressors, such as oxidants, high temperatures, lack of serum, heavy metals, HIV-1 infections, etc.
  • stressors such as oxidants, high temperatures, lack of serum, heavy metals, HIV-1 infections, etc.
  • BAG3 protein influences cell survival in different types of cells, interacting with different molecular partners.
  • A. Rosati et al. Cell Death Dis. (2011) 2:e141 The first mechanism reported in relation to BAG3 anti-apoptotic activity was identified in osteosarcoma and melanoma cells, where it was observed that BAG3 protein modulates the activation of transcription factor NF-kB and cell survival (Ammirante M. et al., Proc Natl Acad Sci USA 107 (2010) 7497-7502).
  • BAG3 protein cooperates in a positive way with HSP70 protein to maintain BAX protein in the cytosol and prevent the translocation thereof into the mitochondria (Festa M. et al., Am J Pathol 178 (2011) 2504-25). Finally, in some tumours, BAG3 has been shown to regulate proteins that modulate cell adhesion.
  • cytoplasmic BAG3 protein has also been described in many different cellular systems and has been associated, not only with various tumours, but also in pathologies in general related to cell survival.
  • patent application n. WO2011/067377 describes soluble BAG3 protein, secreted externally to the cell, as a biochemical marker in serum, which is highly specific for the diagnosis of certain pathological conditions, such as cardiac pathologies and pancreatic tumour.
  • concentration of (extra-cellular) soluble BAG3 is generally greater than 10 ng/ml.
  • BAG3 protein is expressed in 346/346 patients with pancreatic ductal adenocarcinoma (PDAC) and is released by the cells of the pancreatic tumour, but such protein is not expressed in either the surrounding non-neoplastic tissues or in a normal pancreas; likewise, it has been reported that the levels of BAG3 expression are related to patient survival.
  • PDAC pancreatic ductal adenocarcinoma
  • any of the anti-BAG3 antibodies described in patent application n. WO03/055908 able to inhibit, specifically, the activity of soluble BAG3 protein (i.e. extra-cellular) on macrophages, that are considered the target cells proves particularly effective in the treatment of those pathologies characterised by the activation of macrophages, such as neoplastic diseases and diseases of an inflammatory, immune, or degenerative nature.
  • these specific antibodies for BAG3 can bind and block, in a highly selective and targeted manner, pathological effects related to BAG3 protein when secreted by cells.
  • anti-BAG3 antibodies in this process has the surprising advantage of being more specific for the selected pathological states characterised by the over-expression and release of BAG3 protein, and also less damaging in terms of side effects.
  • soluble BAG3 protein is understood as extra-cellular BAG3 protein, i.e. the protein secreted externally to the cell.
  • One aim of the present invention is therefore the use of anti-BAG3 antibodies as a medicament.
  • the antibodies useable in accordance with the present invention may be either monoclonal or polyclonal antibodies, and are preferably monoclonal antibodies.
  • said monoclonal antibodies may be chosen from the following: murinr antibodies, humanised antibodies, chimeric antibodies, recombinant antibodies, conjugated antibodies, scFv fragments (diabody, triabody and tetrabody), Fab fragments, and fragments F (ab′) 2.
  • polyclonal antibody refers to a mixture of antibodies which are genetically different since produced by different plasma cells and which recognise a different epitope of the same antigen.
  • the term “monoclonal antibody” refers to a set of antibodies which are all identical since produced by cell lines from only one type of immune cell (i.e. a cell clone).
  • humanized antibody refers to an antibody of human origin, whose hypervariable region has been replaced by the homologous region of non-human monoclonal antibodies.
  • chimeric antibody refers to an antibody containing portions derived from different antibodies.
  • recombinant antibody refers to an antibody obtained using recombinant DNA methods.
  • conjugated antibody refers to antibodies conjugated with drugs, toxins, radioactive substances or other agents.
  • scFv fragment single chain variable fragment refers to immunoglobulin fragments only capable of binding with the antigen concerned. ScFv fragments can also be synthesised into dimers (diabodies), trimers (triabodies) and tetramers (tetrabodies) using peptide linkers.
  • Fab fragment (antigen-binding fragment) and “Fab2 fragment” refer to immunoglobulin fragments consisting of a light chain linked to the Fc fragment of the adjacent heavy chain, and such fragments are monovalent antibodies. When the Fab portions are in pairs, the fragment is called Fab2.
  • hybrida refers to a cell producing monoclonal antibodies.
  • the monoclonal antibodies used in the examples were obtained by immunising mice against four distinct BAG3 protein peptides using any method known to a person skilled in the art. Such peptides were chosen because they are BAG3 protein-specific and are not shared with any other protein, including BAG proteins.
  • sequences of the four peptides are included in the BAG3 amino acid sequence (RefSeq: NP — 004272; Gene ID 9531) and are selected from the following:
  • SEQ ID NO 1 DRDPLPPGWEIKIDPQ; (includes BAG3 protein amino acids 18-33); SEQ ID NO 2: SSPKSVATEERAAPS; (includes BAG3 protein amino acids 385-399); SEQ ID NO 3: DKGKKNAGNAEDPHT; (includes BAG3 protein amino acids 533-547); SEQ ID NO 4: NPSSMTDTPGNPAAP; (includes BAG3 protein amino acids 561-575).
  • said antibodies may be obtained by means of the Multiple Antigene Peptide approach (MAP) (Keah H H et al., J Pept Res (1988); 51: 2. Tam J P; Proc Natl acad Sci USA (1988), 85: 5409. Ota S, et al., Cancer Res (2002), 62: 1471), using the following map constructs:
  • MAP Multiple Antigene Peptide approach
  • MAP-BAG3-1 nh2-DRDPLPPGWEIKIDPQ-MAP (which contains sequence SEQ ID NO: 1);
  • MAP-BAG3-2 nh2-SSPKSVATEERAAPS-MAP (which contains sequence SEQ ID NO: 2);
  • MAP-BAG3-3 nh2-DKGKKNAGNAEDPHT-MAP (which contains sequence SEQ ID NO: 3);
  • MAP-BAG3-4 nh2-NPSSMTDTPGNPAAP-MAP (which contains sequence SEQ ID NO: 4);
  • said polyclonal anti-BAG3 antibodies are obtained by immunising the animals against one of the four peptides of the sequences SEQ ID NO. 1-4 stated above.
  • the monoclonal anti-BAG3 antibodies of the present invention are obtained by means of a standard procedure (Tassone P., et al., Tissue Antigens 51: 671 (1998)) using the four MAP-BAG3 peptides described above and are produced by at least one of the nine mother clones chosen from the following: AC-1, AC-2, AC-3, AC-4, AC-5, AC-6, AC-7, AC-8, or AC-9 (described in WO03/055908), which contain specific hybridomas for each of the four MAP-BAG3 constructs used.
  • the antibodies used are monoclonal anti-BAG3 antibodies obtained from at least one of the aforesaid mother clones, and preferably at least one chosen from the following: AC-1, AC-2, AC-3, AC-4, or AC-5. More preferably, said monoclonal antibodies are obtained from at least one mother clone chosen from the following: AC-1, AC-2, and AC-3.
  • the monoclonal anti-BAG3 antibodies envisaged in the present invention are obtained from at least one of the following clones: AC-rb1, AC-rb2, AC-rb3 and AC.rb4, and/or at least one of the following subclones: AC-rb1a, AC-rb1b, AC-rb2a, AC-rb2b, AC-rb3a, AC-rb3b, AC-rb4a, and AC-rb4b.
  • the monoclonal antibodies produced by all these clones and subclones recognise the BAG3 recombinant protein in an ELISA test. (Example 2).
  • said monoclonal anti-BAG3 antibodies are those that recognise epitopes in the BAG3 protein amino acid sequence, which include at least one of the following fragments: 18-33, 385-399, 533-547 or 562-575.
  • a further aim of the present invention is the use of the aforesaid anti-BAG3 antibodies in the treatment of a particular pathological state which involves the activation of macrophages.
  • pathological state can be chosen from: neoplastic diseases, inflammatory diseases, immune diseases, and/or degenerative diseases.
  • such neoplastic diseases may be either pancreatic tumour or bladder tumor, more preferably pancreatic tumour.
  • said inflammatory diseases can be chosen from diseases related to inflammation of the skin, nerves, bones, blood vessels, and connective tissues, and more preferably, psoriasis, arthritis, neuritis, connectivitis.
  • said immune diseases can be chosen from autoimmune diseases such as rheumatic diseases, connective tissue diseases, neuromuscular diseases, endocrine diseases, gastrointestinal diseases, haematologic diseases, skin diseases, and vasculitis, and more preferably, rheumatoid arthritis, multiple sclerosis, connectivitis, lupus erythematosus, endometriosis, and ulcerative colitis.
  • said degenerative diseases can be chosen from neurodegenerative diseases and muscular degenerative diseases, and more preferably Alzheimer's disease, Parkinson's disease, and muscular dystrophy.
  • the anti-BAG3 antibodies are used in the treatment of neoplastic diseases, inflammatory diseases, immune diseases, and degenerative diseases.
  • a further aim of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising the aforesaid anti-BAG3 antibody in association with at least one pharmaceutically acceptable excipient.
  • a further object of the present invention is the use of said composition as a medicament.
  • a preferred embodiment of the present invention is the use of the composition in the treatment of neoplastic diseases and diseases of an inflammatory, immune and/or degenerative nature.
  • composition of the present invention can be formulated in a form suitable for oral administration or in a form suitable for parenteral or topical administration.
  • said oral form can be chosen from the following: tablets, capsules, solutions, suspensions, granules, and oily capsules.
  • said topical form can be chosen from the following: cream, ointment, ointment, solution, suspension, eye drops, pessary, nebuliser solution, spray, powder, or gel.
  • said parenteral form can be either an aqueous buffer solution or an oily suspension.
  • Said parenteral administration include administration by intramuscular, intravenous, intradermal, subcutaneous, intraperitoneal, intranodal, or intrasplenic means.
  • FIG. 1 Picture showing the reduction of tumour growth in mice treated with AC-rb2.
  • FIG. 2 Results of the reduction of tumour growth in situ.
  • FIG. 3 Results of reduction of tumour growth in the surrounding area.
  • mice Nude mice (nu/nu) female BALB/c 6 weeks (Charles Rivers Wilmington, Mass., USA) were caged (3 per cage) with food and water ad libitum and kept in 12 h light/dark cycles in standard, pathogen-free conditions.
  • the research protocol was approved by the Ethics Committee in accordance with Italian Ministry of Health official guidelines. After one week of acclimatisation, the mice were subjected to inoculation of cancer cells. 10 mice were used in total, each one individually identified. The entire experiment was conducted in laminar flow hoods and all surgical procedures were performed in strict compliance with aseptic techniques.
  • mice were anesthetised with 100 mg/ml of ketamine HCl and 20 mg/ml of xylazine injected intraperitoneally; they were then subjected to laparotomy and the tail of the pancreas was gently exteriorised.
  • MIA-PaCa 2 RFP cells (2.5 ⁇ 10 6 ) were resuspended in 40 microlitres of PBS 1 ⁇ in a 1 ml syringe; using a 25 G needle, the cells were injected into the tail of the pancreas and the injection point was swabbed with sterile cotton. Once homeostasis was ascertained, the tail of the pancreas was repositioned in the abdomen and the wound closed.
  • mice were randomised into two groups: the first received an intraperitoneal injection of 100 mg/kg of mouse IgG and the second 100 mg/kg of a murine monoclonal anti-BAG3 antibody (AC-rb2). This treatment was performed twice a week in total and the mice were then anesthetised again to check the tumour area using Macro Fluo and LAS V3.7 software, by Leica Mycrosystems Ltd. In each imaging, the tumour mass was determined by quantification of the fluorescent area.
  • AC-rb2 murine monoclonal anti-BAG3 antibody
  • FIGS. 1-3 demonstrate that the treatment with the Anti-BAG3 AC-rb2 antibody reduces the growth of the tumour mass by over 75% in situ and over 45% considering the area surrounding the tumour, i.e. the spread of the tumour.
  • the NUNC Maxisorp 96-well microtitre plates were functionalised with BAG3 recombinant protein 1 ⁇ g/ml in PBS 1 ⁇ pH 7 (50 ⁇ l/well) and incubated for 18 hours at 4° C. The plates were then washed twice with a buffer wash (PBS 1 ⁇ +0.05% Tween-20), and then kept in place for one hour at room temperature with 0.5% fish gelatin in PBS 1 ⁇ (150 ⁇ l/well).
  • the plates were buffer-washed twice and the supernatants of the eight subclones were diluted 1/10, 1/100, and 1/1000, in a 0.5% fish gelatin in PBS 1 ⁇ and then incubated (50 ⁇ l/well) in triplicate and incubated at room temperature for 2 hours. The plates were then buffer-washed six times. To develop the signal, murine anti-IgG antibodies (H+L) (Sigma Aldrich) were used, diluted in the same buffer 1/20,000, then added to the plate (50 ⁇ l/well) and incubated at 4° C. for 30 minutes.
  • H+L murine anti-IgG antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Multiple-Way Valves (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US14/651,213 2012-03-18 2014-03-04 Anti-bag3 antibodies for therapeutic use Abandoned US20150329622A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2013A000403 2013-03-18
IT000403A ITMI20130403A1 (it) 2013-03-18 2013-03-18 Anticorpi anti-bag3 per uso terapeutico
PCT/IB2014/059416 WO2014147503A2 (en) 2013-03-18 2014-03-04 Anti-bag3 antibodies for therapeutic use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/059416 A-371-Of-International WO2014147503A2 (en) 2012-03-18 2014-03-04 Anti-bag3 antibodies for therapeutic use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/141,911 Continuation US11117957B2 (en) 2012-03-18 2018-09-25 Anti-BAG3 antibodies for therapeutic use

Publications (1)

Publication Number Publication Date
US20150329622A1 true US20150329622A1 (en) 2015-11-19

Family

ID=48227407

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/651,213 Abandoned US20150329622A1 (en) 2012-03-18 2014-03-04 Anti-bag3 antibodies for therapeutic use
US16/141,911 Expired - Fee Related US11117957B2 (en) 2012-03-18 2018-09-25 Anti-BAG3 antibodies for therapeutic use

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/141,911 Expired - Fee Related US11117957B2 (en) 2012-03-18 2018-09-25 Anti-BAG3 antibodies for therapeutic use

Country Status (9)

Country Link
US (2) US20150329622A1 (https=)
EP (1) EP2976104B1 (https=)
JP (1) JP6475225B2 (https=)
KR (1) KR20150129649A (https=)
CN (1) CN104902927A (https=)
CA (1) CA2895472C (https=)
ES (2) ES2721935T3 (https=)
IT (1) ITMI20130403A1 (https=)
WO (1) WO2014147503A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109923127A (zh) * 2016-11-07 2019-06-21 比奥尤尼沃萨有限责任公司 用于治疗性用途的抗bag3抗体与免疫检查点抑制剂的组合

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131351A1 (it) 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
ITUB20155097A1 (it) * 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
CN105769900A (zh) * 2016-03-22 2016-07-20 山西大学 Bag3基因在制备抗膀胱癌药物中的应用
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
CN114533877B (zh) * 2022-03-09 2023-07-04 上海交通大学医学院附属第九人民医院 Bag3抑制剂在制备治疗瘢痕产品中的用途
WO2026074330A1 (en) 2024-10-01 2026-04-09 Fibrosys S.R.L. Antibodies and diagnostic methods for detecting bag3 protein in clinical samples

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000014106A1 (en) * 1998-09-09 2000-03-16 The Burnham Institute Novel bag proteins and nucleic acid molecules encoding them
US20050176660A1 (en) * 2001-12-28 2005-08-11 Arturo Leone Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases, and for modulation of cell survival and/or death

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014759A2 (en) * 2007-07-25 2009-01-29 The Trustess Of Columbia University In The City Of New York Methods of inhibiting vzv replication and related compositions
IT1397083B1 (it) * 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
EP2676966A1 (en) * 2012-06-19 2013-12-25 Biouniversa S.r.l. BAG3 as biochemical serum and tissue marker

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000014106A1 (en) * 1998-09-09 2000-03-16 The Burnham Institute Novel bag proteins and nucleic acid molecules encoding them
US20050176660A1 (en) * 2001-12-28 2005-08-11 Arturo Leone Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases, and for modulation of cell survival and/or death

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Behl, Christian (Trends in Pharmacological Sciences 37(8): 672-688, August 2016). *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109923127A (zh) * 2016-11-07 2019-06-21 比奥尤尼沃萨有限责任公司 用于治疗性用途的抗bag3抗体与免疫检查点抑制剂的组合

Also Published As

Publication number Publication date
WO2014147503A3 (en) 2014-12-04
ITMI20130403A1 (it) 2014-09-19
CN104902927A (zh) 2015-09-09
JP2016516078A (ja) 2016-06-02
ES2650942T3 (es) 2018-01-23
WO2014147503A2 (en) 2014-09-25
JP6475225B2 (ja) 2019-02-27
ES2721935T3 (es) 2019-08-06
US20190010221A1 (en) 2019-01-10
CA2895472A1 (en) 2014-09-25
KR20150129649A (ko) 2015-11-20
EP2976104A2 (en) 2016-01-27
EP2976104B1 (en) 2019-01-30
US11117957B2 (en) 2021-09-14
CA2895472C (en) 2022-07-05

Similar Documents

Publication Publication Date Title
US11117957B2 (en) Anti-BAG3 antibodies for therapeutic use
US20220162331A1 (en) Anti-cd73 monoclonal antibody and application thereof
KR102166083B1 (ko) 브라디키닌 b1 수용체 리간드에 대한 항체
ES2724364T3 (es) Procedimiento de tratamiento de fibrosis pulmonar idiopática
BR112020009707A2 (pt) anticorpos para a-sinucleína e usos dos mesmos
CN111491661B (zh) M(h)dm2/4的抗体及其在诊断和治疗癌症中的用途
US10035848B2 (en) Antibody targeting cell surface deposited complement protein C3d and use thereof
JP7645544B2 (ja) Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体
WO2022237647A1 (zh) 针对dll3的结合分子及其应用
US9963514B2 (en) BAG3 receptor binding molecules for use as a medicament
AU2017207082A1 (en) Anti-Myl9 antibody
CN112770786B (zh) 利用抗体的癌症治疗
WO2019020734A1 (en) ANTI-BAG3 ANTIBODIES AS THERAPEUTIC REAGENTS IN CARDIOVASCULAR DISEASES
KR20250008730A (ko) Ror1-표적화 결합 분자 및 이의 용도
HK40022840B (zh) 抗α-突触核蛋白抗体及其用途
HK1206754B (en) Antibodies to bradykinin b1 receptor ligands

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOUNIVERSA S.R.L., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TURCO, MARIA CATERINA;REEL/FRAME:036242/0090

Effective date: 20150624

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION